Grace Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Grace Therapeutics, Inc. (GRCE) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2026-03-31, per its 10-K filed 2026-06-18.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-06-18
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $201.00K.
- 2025-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.63M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-03-31 | $0.00 10-K · filed 2026-06-18 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-12 |
| 2025-09-30 | $201.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.63M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.14M 10-K · filed 2026-06-18 |
| 2024-12-31 | $3.78M 10-Q · filed 2026-02-12 |
| 2024-09-30 | $2.60M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $2.96M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $4.36M 10-K · filed 2026-06-18 |
| 2023-12-31 | $3.33M 10-Q · filed 2025-02-13 |
| 2023-09-30 | $3.46M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 |
| 2023-03-31 | $0.00 10-K · filed 2025-06-23 |
| 2022-12-31 | $0.00 10-Q · filed 2024-02-12 |
| 2022-03-31 | $10.00K 10-K · filed 2024-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |